These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32305776)

  • 1. Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?
    Patoulias D; Papadopoulos C; Doumas M
    Diabetes Metab Syndr; 2020; 14(4):347. PubMed ID: 32305776
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?
    Patoulias D; Papadopoulos C; Doumas M
    Int J Cardiol; 2021 Jan; 323():259. PubMed ID: 32810546
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Liu M; Hao G
    Eur J Prev Cardiol; 2023 Jun; 30(8):656-657. PubMed ID: 36740456
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium-glucose co-transporter-2 inhibitors: know the patient and the drugs.
    Lim LL; Chan JCN
    Hong Kong Med J; 2019 Aug; 25(4):268-270. PubMed ID: 31416989
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?
    Patoulias D; Katsimardou A; Kalogirou MS; Karagiannis A; Doumas M
    Dig Liver Dis; 2020 Feb; 52(2):239-240. PubMed ID: 31787555
    [No Abstract]   [Full Text] [Related]  

  • 6. First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.
    Dziewięcka E; Winiarczyk M; Gliniak M; Kaciczak M; Wiśniowska-Śmiałek S; Karabinowska A; Holcman K; Kostkiewicz M; Hlawaty M; Leśniak-Sobelga A; Podolec P; Rubiś P
    Cardiol J; 2020; 27(5):639-641. PubMed ID: 32789840
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on the Risk for New-Onset Obstructive Sleep Apnea in Patients With Type 2 Diabetes Mellitus Regardless of Cardiovascular Disease at Baseline.
    Patoulias D; Dimosiari A; Michailidis T; Roditis P; Lampropoulos S
    Am J Cardiol; 2022 Sep; 179():116-117. PubMed ID: 35868896
    [No Abstract]   [Full Text] [Related]  

  • 10. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Agents for the Treatment of Type 2 Diabetes.
    Libianto R; Ekinci EI
    Crit Care Clin; 2019 Apr; 35(2):315-328. PubMed ID: 30784612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium-glucose co-transporter type-2 inhibitors: is the message getting through? A reply.
    Nathanson M
    Anaesthesia; 2019 May; 74(5):680. PubMed ID: 30957885
    [No Abstract]   [Full Text] [Related]  

  • 14. Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease.
    Patoulias D; Papadopoulos C; Fragakis N; Karagiannis A; Doumas M
    Am J Cardiol; 2022 Jul; 174():188-189. PubMed ID: 35550822
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter-2 inhibitors, gut microbiota, and atherosclerotic cardiovascular disease: Another mountain to conquer?
    Patoulias D; Kassimis G; Fragakis N
    Pharmacol Res; 2023 Jan; 187():106619. PubMed ID: 36535570
    [No Abstract]   [Full Text] [Related]  

  • 17. A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection.
    Fralick M; MacFadden DR
    Diabetes Obes Metab; 2020 May; 22(5):755-758. PubMed ID: 31943733
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
    Volpe M; Gallo G
    Cardiovasc Res; 2021 Jul; 117(9):1992-1994. PubMed ID: 33231613
    [No Abstract]   [Full Text] [Related]  

  • 19. Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices.
    Patoulias D; Doumas M; Papadopoulos C
    Am J Cardiol; 2022 Jun; 172():169-170. PubMed ID: 35382927
    [No Abstract]   [Full Text] [Related]  

  • 20. How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.
    Zaina A; Prencipe N; Golden E; Berton AM; Arad E; Abid A; Shehadeh J; Kassem S; Ghigo E
    Endocrine; 2023 Jun; 80(3):491-499. PubMed ID: 37000406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.